Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with stable asthma.~* Tidal breathing PC20≤16 mg/mL.~* Baseline FEV1 more than 65% of predicted normal.~* Able to complete 3 methacholine challenges on 3 separate days at the same time of day, at least 24-hours apart and within a 2-week period. (1 during screening and the other 2 during the study)~Exclusion Criteria:~* Airway infection or allergen exposure during the last 4 weeks.~* Exacerbation during the last 4 weeks.~* Change in dosage of inhaled or oral steroids during the last 4 weeks.~* Inhaled salbutamol less than 8 hours prior to testing.~* Inhaled formoterol or salmeterol less than 36 hours prior to testing.~* Antihistamines during the last 48 hours.~* Chronic health conditions that are determined by the principal investigator to be significant (eg cystic fibrosis).~* Smokers~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 'The English-Wright nebulizer' (Type: ACTIVE_COMPARATOR): The English-Wright nebulizer will be used to perform a methacholine challenge.
- Trudell AeroEclipse*II BAN nebulizer (Type: ACTIVE_COMPARATOR): The Trudell AeroEclipse\*II BAN nebulizer will be used to perform a methacholine challenge

Based on this trial design, predict the completion outcome and termination type (if applicable).